Halozyme Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

HALO 8.99 -0.41 (-4.36%)
price chart
Baxter and Halozyme Therapeutics Get FDA Approval
Halozyme Therapeutics is a biopharmaceutical company that develops advanced patient care products. The company mainly focuses on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs ...
Active Stocks: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Nucor Corporation ...  USTrade Voice
FDA Approves Baxter's HYQVIA for Treatment of Adults with Primary ...  MarketWatch
Related articles »  
Halozyme Is Worth Betting On (HALO)
Despite the tremendous potential of PEGPH20, news of the Fast Track Designation did not have a major impact on the stock. But I believe that Halozyme Therapeutics should not be ignored, given that it is developing what could be a potential blockbuster ...
Related articles »  
Why Halozyme Is Up 8%
Halozyme Therapeutics, Inc. (HALO) and Baxter International Inc. (BAX) were up in extended trading yesterday, after both companies announced that US Food and Drug Administration (FDA) had granted approval to their immune globulin therapy, HYQVIA for ...
Halozyme Therapeutics Receives Underperform Rating from Jefferies Group ...
Halozyme Therapeutics, Inc. logo Halozyme Therapeutics (NASDAQ:HALO)'s stock had its �underperform� rating reaffirmed by equities researchers at Jefferies Group in a research report issued on Monday.
Related articles »  
Momentum Stocks: Pfizer Inc. (NYSE:PFE), Halozyme Therapeutics, Inc ...
On 3 September Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human ...
Morning Watch List : Halozyme Therapeutics (NASDAQ:HALO), Novavax ...
On September 03, 2014,Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human ...
Related articles »  
Trader's Recap: Halozyme Therapeutics (NASDAQ:HALO), FuelCell Energy Inc ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) on 4 September announced that the FDA has given fast track designation to its program investigating PEGPH20 as part of a combination treatment for patients with metastatic pancreatic cancer.
Why You Shouldn't Bet Against Halozyme Therapeutics (HALO) Stock - Tale of ...
One stock that might be an intriguing choice for investors right now is Halozyme Therapeutics, Inc. ( HALO ). This is because this security in the Med-Biomed/Gene space is seeing solid earnings estimate revision activity, and is in great company from a ...
Related articles »  
Markets Watch: Tetraphase Pharmaceuticals Inc (TTPH), Vince Holding Corp ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that the FDA has granted Fast Track designation for Halozyme Therapeutics, Inc. (NASDAQ:HALO) program investigating PEGPH20 in combination with gemcitabine and nab-paclitaxel for the ...
Related articles »  
Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast ...
3, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. HALO, -2.55% today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human ...
Halozyme Therapeutics (HALO) PEGPH20 Granted Fast Track Designation  StreetInsider.com (subscription)
Related articles »